Tesamorelin
WellnessAlso known as: Egrifta, Egrifta SV, Egrifta WR, TH9507, GHRH Analog
Well-StudiedWhat is Tesamorelin?
The only FDA-approved peptide specifically indicated for visceral fat reduction. A synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH), tesamorelin stimulates the pituitary to produce endogenous GH rather than supplying exogenous growth hormone directly. Widely used off-label in anti-aging and body composition protocols.
How it works
Binds pituitary GHRH receptors and triggers pulsatile, physiologic growth hormone secretion, which in turn raises IGF-1 levels. The added trans-3-hexenoic acid group at the N-terminus protects the peptide from enzymatic degradation, extending half-life. Because it works through the body's own feedback system rather than bypassing it, tesamorelin preserves the natural pulsatile GH release pattern — a key distinction from exogenous HGH therapy.
What marketers claim
- ▸melts all body fat like HGH
- ▸replaces testosterone therapy
- ▸reverses aging completely
- ▸no side effects because it's natural
What evidence supports
- ✓FDA-approved for visceral fat reduction in HIV-associated lipodystrophy (2010; Egrifta WR reformulation approved March 2025)
- ✓pivotal NEJM trial (n=412) showed 15.2% reduction in visceral adipose tissue vs 5.1% placebo over 26 weeks
- ✓JAMA study demonstrated 37% reduction in liver fat vs 5% in placebo group in HIV patients
- ✓stimulates endogenous GH via preserved pituitary feedback — does not suppress natural GH axis
- ✓search volume growing 49% over 6 months to >135,000 monthly searches (Feb 2026)
Research evidence
Key studies on Tesamorelin, summarized in plain language. This is not an exhaustive list — it highlights the most relevant findings.
Metabolic effects of a growth hormone-releasing factor in patients with HIV
Finding: Tesamorelin reduced visceral adipose tissue by 15.2% vs 5.1% with placebo over 26 weeks. Significant improvements in triglycerides and waist circumference. This was the pivotal trial supporting FDA approval.
Limitation: Study conducted exclusively in HIV-infected patients with lipodystrophy — results may not generalize to non-HIV populations or those without established lipodystrophy.
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation
Finding: Tesamorelin reduced visceral adipose tissue by 18% and liver fat content by 37% (vs 5% in placebo) as measured by MRI and CT. Liver fat reduction was independent of BMI changes.
Limitation: Small sample size. HIV-only population. Study duration was 26 weeks — long-term liver outcomes are not established.
FDA approval: Egrifta WR (tesamorelin F8 formulation)
Finding: Bioequivalence study demonstrated similar efficacy and safety of the new F8 formulation vs the original Egrifta SV. Improved reconstitution and smaller injection volume confirmed. FDA approved March 25, 2025.
Limitation: Regulatory approval study focused on bioequivalence, not additional efficacy endpoints beyond those established in original pivotal trials.
Best for
What to expect
Realistic timeline based on available research. Individual results vary.
Week 1–4
Many users report improved sleep quality within the first weeks as GH pulses are amplified during slow-wave sleep. No visible body composition changes yet.
Month 2–3
Early reductions in waist circumference possible. IGF-1 levels begin rising measurably. Some users notice improved energy and body composition.
Month 4–6
Meaningful visceral fat reductions visible in clinical imaging. The pivotal NEJM trial showed significant VAT change by week 26. Subcutaneous fat is less affected.
Month 6+
FDA approval studies ran to 52 weeks with continued improvement. Discontinuation typically results in gradual return of visceral fat over subsequent months.
Safety notes & concerns
Full safety guide →- ⚠FDA-approved only for HIV-associated lipodystrophy — off-label use for anti-aging or body composition is not approved
- ⚠common side effects include joint pain (arthralgia), mild fluid retention (edema), and injection-site redness
- ⚠raises IGF-1 levels — periodic IGF-1 monitoring is essential; elevated IGF-1 is associated with theoretical cancer risk
- ⚠contraindicated with active malignancy or history of pituitary tumor, head radiation, or surgery
- ⚠mild elevations in fasting glucose and A1c have been observed — metabolic monitoring required
- ⚠not appropriate during pregnancy
- ⚠prescription-only in most jurisdictions; off-label compounded versions vary widely in quality
Pairs well with
Use caution with
Frequently asked questions
Is tesamorelin the same as HGH?
No. Tesamorelin is a GHRH analog — it stimulates your own pituitary gland to produce growth hormone naturally. Exogenous HGH bypasses this system entirely. Because tesamorelin works through the body's feedback loops, GH release remains pulsatile and self-regulated, which is considered safer than direct HGH injection.
Can tesamorelin be used for weight loss without HIV?
Its FDA approval is specifically for HIV-associated lipodystrophy. Off-label use for general weight loss or anti-aging is common in longevity clinics but is not supported by randomized controlled trials in non-HIV populations. A physician must prescribe it for any indication.
What is Egrifta WR?
Egrifta WR is a newer formulation of tesamorelin approved by the FDA in March 2025. It provides the same efficacy as the original Egrifta SV but with a simplified reconstitution process and weekly rather than daily preparation, improving adherence.
How is tesamorelin different from CJC-1295?
Both are GHRH analogs that stimulate GH release, but tesamorelin is FDA-approved with extensive clinical trial data, while CJC-1295 is a research chemical without FDA approval for any use. Tesamorelin is the 44-amino-acid full GHRH sequence; CJC-1295 is a modified 30-amino-acid fragment. Tesamorelin's evidence base in humans is considerably stronger.
Related wellness peptides
those interested in experimental recovery support with medical supervision
skin hydration support, joint comfort, general wellness
clinically obese patients under physician supervision, type 2 diabetes management
those following longevity research who pursue protocols with medical supervision
Take the Peptide Quiz
Get personalized recommendations
Stack Builder
Build a routine with Tesamorelin
Last updated: 2026-05-13
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.